



ASX Release

14 January 2019

A FURTHER TWO KEY OPINION LEADERS APPOINTED TO UNDERTAKE FELIX ASSESSMENT

Highlights

- **Memphasys signs MoUs with an additional two Key Opinion Leaders (KOLs) to separately take part in *in-vitro* assessments of the Felix device.**
- **These independent studies will be led by highly published international leaders from highly acclaimed centres in reproductive medicine and andrology.**

Australian-based bio-separations company Memphasys Limited (ASX: MEM) (“Memphasys” or “the Company”) is pleased to announce it has signed two further Memorandums of Understanding (“MoUs”) with globally significant research and clinical service centres, Boston IVF (USA) and the University of Munster (Germany) and to take part in *in-vitro* assessments of the Felix device.

Memphasys has now signed and announced a total of seven KOL to participate in its commercial Felix assessment program. The two latest KOLs are as follows:

Boston IVF (USA) – Dr Denny Sakkas

Boston IVF, affiliated with The Beth Israel Deaconess Medical Center and Harvard University's School of Medicine, runs one of the largest IVF centres in the USA and operates five clinics in other US states. Boston IVF conducts ground-breaking research that has contributed to vast improvements in fertility treatments and care for over three decades.

The Boston IVF team will be led by Dr. Denny Sakkas, Associate Professor at the Department of Obstetrics, Gynecology and Reproductive Sciences at the Yale University School of Medicine. Dr Sakkas is also the Scientific Director at Boston IVF.

Dr Sakkas previously headed a successful Gamete Biology Research Team and served as the Director of Assisted Reproductive Treatment Laboratories of the Yale Fertility Center. Formerly, Dr. Sakkas was the Laboratory Director of IVF units in Switzerland and England and has aided numerous groups in establishing their own IVF units around the world.

He has extensive experience in clinical IVF and reproductive research. A highly published author in the field of fertilisation, early embryo development and male infertility, he is on the Editorial Board of five leading journals. His PhD, in reproductive research, was from Monash University, Melbourne.

Centre of Reproductive Medicine and Andrology, (“CeRA”), University of Münster (Germany) – Prof Stefan Schlatt

CeRA is a Center of Excellence in Germany for research and clinical service in andrology and reproduction. It consists of the Institute of Reproductive and Regenerative Biology, the Department of Clinical Andrology and the Assisted Reproduction Unit. Its research is dedicated to solving

important questions in basic reproductive functions and clinical applications, providing patient benefits at the earliest opportunity.

Professor Stefan Schlatt is Director of CeRA at the University of Münster, Germany.

Professor Schlatt is a much published international leader in reproductive medicine. His focus is on human and animal gonadal development and physiology and stem cells in the testes.

During his career he has led research at Monash University, University of Pennsylvania, and University of Pittsburgh, in addition to University of Münster.

Under the terms of the two MoUs signed, Dr Denny Sakkas and Professor Stefan Schlatt will separately participate with world-renowned fertility expert and co-inventor of the Felix technology, Prof John Aitken from the University of Newcastle, and Memphasys in the clinical validation of the Felix device.

They will independently and collaboratively work with Prof Aitken to validate the Felix system and confirm its application and efficacy in separating spermatozoa under clinical conditions from a range of clinical samples of human semen.

Memphasys has now signed the following KOL centres to undertake assessment studies of the Felix device as part of Felix's commercialisation process.

Key Opinion Leader Centre		ASX Announcement
1	ANOVA Karolinska, Stockholm, Sweden	22 October 2018
2	Genetics, Reproduction and Development Laboratory at University Clermont, Auvergne ("UCA/GReD"), France	22 November 2018
3	Colorado Center of Reproductive Medicine, ("CCRM"), USA	20 December 2018
4	University of Florence, Italy	11 January 2019
5	Isfahan Fertility & Infertility, Iran	11 January 2019
6	Boston IVF, USA	14 January 2019
7	Centre of Reproductive Medicine and Andrology, ("CeRA"), University of Münster, Germany	14 January 2019

Commenting on the signing of two additional KOLs, Memphasys Executive Chairman, Ms Alison Coutts, said:

"We are delighted that two more major centres led by such world-renowned fertility experts have agreed to be involved in clinical validation of the Felix device as part of its commercialisation process."

"The recruitment of the current seven reference centres represents major IVF markets in the United States, Europe and the Middle East and more will be announced shortly."

As previously outlined, the KOL clinical assessment studies will assess and confirm Felix's performance for IVF clinics in preparing sperm from diverse semen types when compared with the current lab-based methods, ("density gradient centrifuge" and "swim up").

The outcomes of the Felix clinical assessments will provide further evidence as to the technical capabilities and broaden the clinical benefits of the Felix device, provide significant user examples of its range of use and further refine the commercialisation strategy of the Company.

Assessment Protocols

Prof Aitken will develop assessment protocols with each IVF clinic and andrology centre. The Felix assessment program is expected to have two protocols at each site – one general protocol for all IVF clinics and andrology centres, comparing the Felix-selected sperm against the quality of sperm selected by current lab methods (Swim Up/ DGC) with routine clinical semen samples; and a second assessing Felix performance for particular types of male infertility of particular interest to each individual IVF clinic or andrology centre.

ENDS

For further information please contact:

Alison Coutts
Executive Chairman
Memphasys Limited
+61 2 8415 7300
alison.coutts@memphasys.com

David Tasker
Managing Director
Chapter One Advisors
+ 0433 112 936
dtasker@chapteroneadvisors.com.au

About Memphasys:

Memphasys Limited (ASX: MEM) specialises in biological separations for high value commercial applications. The Company's patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.